Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Lancet. Infectious Diseases (Print)

• Publication date

  2013-07-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1473-3099(13)70110-5PMID 23665341
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• References Subscriptions Permissions Email Alerts Inhibition of Borrelia burgdorferi-Tick Interactions In Vivo by Outer Surface Protein A Antibody

  2013cited by this paper
• Lyme borreliosis.

  2012cited by this paper
• A Randomized Trial

  2012cited by this paper
• Differentiation of reinfection from relapse in recurrent Lyme disease.

  2012cited by this paper
• A new approach to a Lyme disease vaccine.

  2011cited by this paper
• Vaccines against Lyme disease: What happened and what lessons can we learn?

  2011cited by this paper
• Correcting a public health fiasco: The need for a new vaccine against Lyme disease.

  2011cited by this paper
• Relationship between immunity to Borrelia burgdorferi outer-surface protein A (OspA) and Lyme arthritis.

  2011cited by this paper
• Safety and immunogenicity of an inactivated whole virus Vero cell-derived Ross River virus vaccine: a randomized trial.

  2011cited by this paper
• Lyme borreliosis in Europe.

  2011cited by this paper
• Lyme borreliosis: clinical case definitions for diagnosis and management in Europe.

  2011cited by this paper
• Correlates of Protection Induced by Vaccination

  2010cited by this paper
• A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.

  2008cited by this paper
• Outer Surface Protein A Protects Lyme Disease Spirochetes from Acquired Host Immunity in the Tick Vector

  2008cited by this paper
• Lyme borreliosis in Europe: influences of climate and climate change, epidemiology, ecology and adaptation measures

  2006cited by this paper
• Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants.

  2005cited by this paper
• Adjuvants and Antibody Production: Dispelling the Myths Associated with Freund's Complete and Other Adjuvants

  2005cited by this paper
• Aluminium adjuvants--in retrospect and prospect.

  2004cited by this paper
• Molecular characterization of the OspA(161-175) T cell epitope associated with treatment-resistant Lyme arthritis: differences among the three pathogenic species of Borrelia burgdorferi sensu lato.

  2004cited by this paper
• An open-label, nonrandomized, single-center, prospective extension, clinical trial of booster dose schedules to assess the safety profile and immunogenicity of recombinant outer-surface protein A (OspA) Lyme disease vaccine.

  2003cited by this paper
• Mechanisms of stimulation of the immune response by aluminum adjuvants.

  2002cited by this paper
• Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice

  2002cited by this paper
• Approaches toward the directed design of a vaccine against Borrelia burgdorferi.

  2002cited by this paper
• Safety and immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against lyme disease in healthy children and adolescents: a randomized controlled trial.

  2001cited by this paper
• Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

  2001cited by this paper
• Safety and immunogenicity profile of a recombinant outer-surface protein A Lyme disease vaccine: clinical trial of a 3-dose schedule at 0, 1, and 2 months.

  2000cited by this paper
• Structural identification of a key protective B-cell epitope in Lyme disease antigen OspA.

  2000cited by this paper
• Vaccination against Lyme Disease with Recombinant Borrelia burgdorferi Outer-Surface Lipoprotein A with Adjuvant

  2000cited by this paper
• Immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against Lyme disease in children.

  1999cited by this paper
• Sensitive and Specific Serodiagnosis of Lyme Disease by Enzyme-Linked Immunosorbent Assay with a Peptide Based on an Immunodominant Conserved Region of Borrelia burgdorferi VlsE

  1999cited by this paper
• Cutting edge: inflammatory signaling by Borrelia burgdorferi lipoproteins is mediated by toll-like receptor 2.

  1999cited by this paper
• Alternative vaccination schedules (0, 1, and 6 months versus 0, 1, and 12 months) for a recombinant OspA Lyme disease vaccine.

  1999cited by this paper
• Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis.

  1998cited by this paper
• Clinical and immunological assessment of a candidate Lyme disease vaccine in healthy adults: antibody persistence and effect of a booster dose at month 12.

  1998cited by this paper
• A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium.

  1998cited by this paper
• Lyme disease vaccines.

  1998cited by this paper
• Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group.

  1998cited by this paper
• Plasminogen is required for efficient dissemination of B. burgdorferi in ticks and for enhancement of spirochetemia in mice.

  1997cited by this paper
• Evaluation of the safety, reactogenicity and immunogenicity of three recombinant outer surface protein (OspA) lyme vaccines in healthy adults.

  1996cited by this paper
• Safety and immunogenicity of an outer surface protein A vaccine in subjects with previous Lyme disease.

  1995cited by this paper
• Safety and immunogenicity of a recombinant outer surface protein A Lyme vaccine.

  1994cited by this paper
• If nothing goes wrong, is everything all right? Interpreting zero numerators.

  1983cited by this paper

• Homologous and Heterologous Immunization with a PIV5-Based Modified OspA Vaccine Confers Equivalent Protection Against Tick-Transmitted Borrelia burgdorferi

  2026cites this paper
• Revolutionizing Lyme disease vaccination: a systematic review and meta-analysis of promising candidates

  2025cites this paper
• A human Lyme disease vaccine: two steps forward on the path to prevention.

  2025cites this paper
• Immunogenicity and safety of different immunisation schedules of the VLA15 Lyme borreliosis vaccine candidate in adults, adolescents, and children: a randomised, observer-blind, placebo-controlled, phase 2 trial.

  2025cites this paper
• A Broadly Conserved Protective Epitope on the Lyme Disease Vaccine Antigen, OspA

  2025cites this paper
• What Stage Are We at in the Development of Vaccines Against Tick-Borne Diseases?

  2025cites this paper
• Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in children, adolescents, and adults in the USA: a randomised, observer-blind, placebo-controlled, phase 2 trial.

  2025cites this paper
• Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in healthy adults in the USA: results of the booster phase of a randomised, controlled, phase 2 trial.

  2024cites this paper
• Intranasal vaccine for Lyme disease provides protection against tick transmitted Borrelia burgdorferi beyond one year

  2024cites this paper
• Research progress toward arthropod salivary protein vaccine development for vector-borne infectious diseases

  2024cites this paper
• Optimisation of dose level and vaccination schedule for the VLA15 Lyme borreliosis vaccine candidate among healthy adults: two randomised, observer-blind, placebo-controlled, multicentre, phase 2 studies.

  2024cites this paper
• Safety and immunogenicity of a novel multivalent OspA-based vaccine candidate against Lyme borreliosis: a randomised, phase 1 study in healthy adults.

  2023cites this paper
• Structural Elucidation of a Protective B Cell Epitope on Outer Surface Protein C (OspC) of the Lyme Disease Spirochete, Borreliella burgdorferi

  2023cites this paper
• Cellular and transcriptome signatures unveiled by single-cell RNA-Seq following ex vivo infection of murine splenocytes with Borrelia burgdorferi

  2023cites this paper
• Pathogenicity and virulence of Borrelia burgdorferi

  2023cites this paper
• A parainfluenza virus 5 (PIV5)-vectored intranasal vaccine for Lyme disease provides long-lasting protection against tick transmitted Borrelia burgdorferi in mice

  2023cites this paper
• VLA15, a new global Lyme disease vaccine undergoes clinical trials.

  2023cites this paper
• Lyme disease transmission by severely impaired ticks

  2022cites this paper
• The year that shaped the outcome of the OspA vaccine for human Lyme disease

  2022cites this paper
• Human B Cell Epitope Map of the Lyme Disease Vaccine Antigen, OspA.

  2022cites this paper
• Past, present, and future of Lyme disease vaccines: antigen engineering approaches and mechanistic insights

  2022cites this paper
• Aluminium adjuvants versus placebo or no intervention in vaccine randomised clinical trials: a systematic review with meta-analysis and Trial Sequential Analysis

  2022cites this paper
• Amplification of the Specific Conformational Fluctuation of Proteins by Site-Specific Mutagenesis and Hydrostatic Pressure.

  2022cites this paper
• A brief history of OspA vaccines including their impact on diagnostic testing for Lyme disease.

  2021cites this paper
• Human and Veterinary Vaccines for Lyme Disease.

  2020cites this paper
• Novel targets and strategies to combat borreliosis

  2020cites this paper
• Broadly Protective Multivalent OspA Vaccine against Lyme Borreliosis, Developed Based on Surface Shaping of the C-Terminal Fragment

  2020cites this paper
• Through Lyme’s Looking Glass

  2020cites this paper
• PREVENTING LYME

  2020cites this paper
• Lyme Disease Outside In

  2020cites this paper
• References

  2020cites this paper
• 5. Lyme Disease, Evidence-Based Medicine, and the Biopolitics of Truthmaking

  2020cites this paper
• DIAGNOSING AND TREATING LYME

  2020cites this paper
• MAPPING THE LYME DISEASE CONTROVERSY

  2020cites this paper
• LYME DISEASE AND RELAPSING FEVER SPIROCHETES

  2020cites this paper
• Lyme borreliosis: diagnosis and management

  2020cites this paper
• LIVING LYME

  2020cites this paper
• Notes

  2020cites this paper
• Cost-effectiveness of a potential anti-tick vaccine with combined protection against Lyme borreliosis and tick-borne encephalitis in Slovenia.

  2019cites this paper
• Diagnóstico y tratamiento de la carditis de Lyme. Revisión JACC Tema de la semana

  2019cites this paper
• Diagnosis and Treatment of Lyme Carditis: JACC Review Topic of the Week.

  2019cites this paper
• Current challenges in the development of vaccines and drugs against emerging vector-borne diseases.

  2019cites this paper
• Spontaneously released Neisseria meningitidis outer membrane vesicles as vaccine platform: production and purification.

  2019cites this paper
• Functionalized Liposomes as Vaccines against Vector-borne Diseases

  2019cites this paper
• Interventions to prevent Lyme disease in humans: A systematic review

  2018cites this paper
• Control of Lyme borreliosis and other Ixodes ricinus-borne diseases

  2018cites this paper
• Lyme borreliosis-from tick bite to diagnosis and treatment.

  2018cites this paper
• Lemons and Lyme.

  2018cites this paper
• 34 – Lyme Disease Vaccines

  2018cites this paper
• Cost-effectiveness of a potential anti-tick vaccine with combined protection against Lyme borreliosis and tick-borne encephalitis in Slovenia

  2018cites this paper
• Ixodes Tick Saliva: A Potent Controller at the Skin Interface of Early Borrelia burgdorferi Sensu Lato Transmission

  2017cites this paper
• Development of a Novel, Peptide-based Vaccine for Lyme Disease

  2017cites this paper
• Hyperbaric Oxygen Therapy and Chronic Lyme Disease: The Controversy and the Evidence

  2017cites this paper
• The novel Lyme borreliosis vaccine VLA15 shows broad protection against Borrelia species expressing six different OspA serotypes

  2017cites this paper
• Safety, immunogenicity, and efficacy of Borrelia burgdorferi outer surface protein A (OspA) vaccine: A meta-analysis.

  2017cites this paper
• Analysis of O2-binding Sites in Proteins Using Gas-Pressure NMR Spectroscopy: Outer Surface Protein A.

  2017cites this paper
• A systematic review and meta-analysis for the adverse effects, immunogenicity and efficacy of Lyme disease vaccines: Guiding novel vaccine development

  2017influential citation
• Chapter 42 – Lyme Disease

  2016cites this paper
• Mycobacterium tuberculosis lipoproteins in virulence and immunity – fighting with a double‐edged sword

  2016cites this paper
• Lyme borreliosis

  2016cites this paper
• Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers.

  2016cites this paper
• Vaccines for tick-borne diseases and cost-effectiveness of vaccination: a public health challenge to reduce the diseases’ burden

  2016influential citation
• Intentions to receive a potentially available Lyme disease vaccine in an urban sample

  2016cites this paper
• 23. Prevention of Lyme borreliosis after a tick bite

  2016cites this paper
• Health economics of tick-borne diseases

  2016cites this paper
• 1. Introduction: choosing a One Health approach for the control of Lyme borreliosis

  2016cites this paper
• The effects of key motility and chemotaxis genes on Borrelia burgdorferi dissemination and evasion of immune clearance in murine tissues

  2015cites this paper
• Borreliose im Kindes- und Jugendalter

  2015cites this paper
• Vaccination against Lyme disease: Are we ready for it?

  2015influential citation
• The growing global battle against blood-sucking ticks

  2015cites this paper
• Vaccines for tick-borne diseases and cost-effectiveness of vaccination: a public health challenge to reduce the diseases’ burden

  2015influential citation
• Lyme borreliosis: reviewing potential vaccines, clinical aspects and health economics

  2015influential citation
• Recent advances in the molecular design of synthetic vaccines.

  2015cites this paper
• Lyme disease vaccination: safety first - authors' reply.

  2014cites this paper
• Lyme disease vaccination: safety first.

  2014cites this paper
• ANTIDotE: anti-tick vaccines to prevent tick-borne diseases in Europe

  2014cites this paper
• Resurrecting the 'yuppie vaccine'

  2014cites this paper
• A Novel Multivalent OspA Vaccine against Lyme Borreliosis Is Safe and Immunogenic in an Adult Population Previously Infected with Borrelia burgdorferi Sensu Lato

  2014influential citation
• A Tick Gut Protein with Fibronectin III Domains Aids Borrelia burgdorferi Congregation to the Gut during Transmission

  2014cites this paper
• Infections of the Posterior Segment: Other Bacterial Infections

  2014cites this paper
• Clinical practice. Lyme disease.

  2014cites this paper
• Lyme disease.

  2014cites this paper
• Design and Development of a Novel Vaccine for Protection against Lyme Borreliosis

  2014cites this paper
• Lyme disease vaccination: safety first - author's reply.

  2014cites this paper
• Evaluation of OspA Vaccination-Induced Serological Correlates of Protection against Lyme Borreliosis in a Mouse Model

  2013cites this paper
• Sensitivity of a point of care tick-test for the development of Lyme borreliosis

  2013cites this paper
• Lyme disease in the United Kingdom

  2013cites this paper
• A novel multivalent OspA vaccine against Lyme borreliosis shows promise in Phase I/II studies

  2013cites this paper
• Lyme disease vaccination: are we ready to try again?

  2013cites this paper
• Lyme disease vaccination: are we ready to try again?

  2013cites this paper